Study Of The Antiischemic Action Of EGb 761 In The Treatment Of Peripheral Arterial Occlusive Disease By TcPo2 Determination
Notes for this study:
|Number of Subjects
In persons with peripheral arterial occlusive disease given 160mg EGb-761 twice daily for a period of 4 weeks, supplementation failed to improve performance on a treadmill test (intermittent claudication) but was effective in reducing the degree of cerebral ischemia associated with exercise. No differences were noted at rest.